Increased P-35, EBI3 transcripts and other treg markers in peripheral blood mononuclear cells of breast cancer patients with different clinical stages

Advanced Pharmaceutical Bulletin

Volumn 5, Issue 2, 2015, Pages 261-267

  Hamidinia, Maryam ^a   Boroujerdnia, Mehri Ghafourian ^a   Talaiezadeh, Abdolhassan ^a   Solgi, Ghasem ^b   Roshani, Reyhaneh ^a   Iranprast, Sara ^a   Khodadadi, Ali ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Foxp3; IL 10; IL 35; TGF

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 35; MESSENGER RNA; PROTEIN P35; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; EBI3 GENE; FEMALE; FOXP3 GENE; GAPDH GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSCRIPTION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; IL10 GENE; LYMPHOCYTE ACTIVATION; MALE; METASTASIS POTENTIAL; P35 GENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTION; QUANTITATIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; RNA TRANSCRIPTION; TGF BETA GENE; VERY ELDERLY;

EID: 84930390701     PISSN: 22285881     EISSN: 22517308     Source Type: Journal    
DOI: 10.15171/apb.2015.036     Document Type: Article

References (32)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11-30. doi: 10.3322/caac.21166.
2. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, et al. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 2008;100(23):1672-94. doi: 10.1093/jnci/djn389.
3. Masoompour SM, Yarmohammadi H, Rezaianzadeh A, Lankarani KB. Cancer incidence in southern Iran, 1998-2002: results of population-based cancer registry. Cancer Epidemiol 2011;35(5):e42-7. doi: 10.1016/j.canep.2011.05.018.
4. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006;16(1):3-15. doi: 10.1016/j.semcancer.2005.07.008.
5. Gavin MA, Rasmussen JP, Fontenot JD, Vasta V, Manganiello VC, Beavo JA, et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007;445(7129):771-5. doi: 10.1038/nature05543.
6. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057-61. doi: 10.1126/science.1079490.
7. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 2005;6(11):1142-51. doi: 10.1038/ni1263.
8. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, Vignali KM, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007;450(7169):566-9. doi: 10.1038/nature06306.
9. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. Curr Opin Pharmacol 2009;9(4):447-53. doi: 10.1016/j.coph.2009.04.008.
10. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003;198(12):1875-86. doi: 10.1084/jem.20030152.
11. Groux H, O'garra A, Bigler M, Rouleau M, Antonenko S, De Vries JE, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389(6652):737-42. doi: 10.1038/39614.
12. Collison LW, Pillai MR, Chaturvedi V, Vignali DA. Regulatory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol 2009;182(10):6121-8. doi: 10.4049/jimmunol.0803646.
13. Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, Mcinnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007;37(11):3021-9. doi: 10.1002/eji.200737810.
14. Schabowsky RH, Madireddi S, Sharma R, Yolcu ES, Shirwan H. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Curr Opin Investig Drugs 2007;8(12):1002-8.
15. Liu Z, Kim JH, Falo LD, Jr., You Z. Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol 2009;182(10):6160-7. doi: 10.4049/jimmunol.0802664.
16. Wang RF. Regulatory T cells and innate immune regulation in tumor immunity. Springer Semin Immunopathol 2006;28(1):17-23. doi: 10.1007/s00281-006-0022-7.
17. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, et al. Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res 2008;14(16):5166-72. doi: 10.1158/1078-0432.ccr-08-0320.
18. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29(9):e45. doi: 10.1093/nar/29.9.e45.
19. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009;21(10):1105-11. doi: 10.1093/intimm/dxp095.
20. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013;14(6):e218-28. doi: 10.1016/s1470-2045(12)70582-x.
21. Horwitz DA, Zheng SG, Gray JD. The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol 2003;74(4):471-8. doi: 10.1189/jlb.0503228.
22. Maynard CL, Weaver CT. Diversity in the contribution of interleukin-10 to T-cell-mediated immune regulation. Immunol Rev 2008;226:219-33. doi: 10.1111/j.1600-065x.2008.00711.x.
23. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy-review of a new approach. Pharmacol Rev 2003;55(2):241-69. doi: 10.1124/pr.55.2.4.
24. Wang R, Lu M, Zhang J, Chen S, Luo X, Qin Y, et al. Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res 2011;30(1):62. doi: 10.1186/1756-9966-30-62.
25. Merendino RA, Arena A, Capozza AB, Chillemi S, Mesiti M. Serum levels of interleukin-10 in patients affected by breast cancer. Immunol Lett 1996;53(1):59-60. doi: 10.1016/0165-2478(96)02598-9.
26. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J Immunol 2004;172(9):5149-53. doi: 10.4049/jimmunol.172.9.5149.
27. Nam JS, Terabe M, Mamura M, Kang MJ, Chae H, Stuelten C, et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 2008;68(10):3835-43. doi: 10.1158/0008-5472.can-08-0215.
28. Pang Y, Gara SK, Achyut BR, Li Z, Yan HH, Day CP, et al. TGF-beta signaling in myeloid cells is required for tumor metastasis. Cancer Discov 2013;3(8):936-51. doi: 10.1158/2159-8290.cd-12-0527.
29. Katz LH, Li Y, Chen JS, Munoz NM, Majumdar A, Chen J, et al. Targeting TGF-beta signaling in cancer. Expert Opin Ther Targets 2013;17(7):743-60.
30. Barcellos-Hoff MH, Akhurst RJ. Transforming growth factor-beta in breast cancer: too much, too late. Breast Cancer Res 2009;11(1):202. doi: 10.1186/bcr2224.
31. Wang Z, Liu JQ, Liu Z, Shen R, Zhang G, Xu J, et al. Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol 2013;190(5):2415-23. doi: 10.4049/jimmunol.1202535.
32. Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol 2010;11(12):1093-101. doi: 10.1038/ni.1952.